After patients enrol in clinical trials, regular assessments and testing – often requiring clinic visits – can become onerous and reduce the chances they will stick with t
In the realm of architectural and construction innovation for healthcare, the NHS is grappling with a formidable challenge: the prolonged backlog for a spectrum of vital medical services an
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh